Patents Examined by Phuong Huynh
  • Patent number: 11073632
    Abstract: A buried utility locator includes an antenna array for receiving magnetic field signals from a buried utility, a receiver operatively coupled to the antenna array for generating a receiver output signal including amplitude and/or phase information of two or more signal components in two or more simultaneously received signals of the frequency suite, a processing element operatively coupled to the receiver for receiving the receiver output signal and generating a first set of data associated with the two or more signal components of the frequency suite, and a non-transitory memory for storing the first set of data.
    Type: Grant
    Filed: June 15, 2020
    Date of Patent: July 27, 2021
    Assignee: SEESCAN, INC.
    Inventors: Mark S. Olsson, Stephanie M. Bench, Michael J. Martin, Ray Merewether, Paul Wisecaver, Austin Rutledge
  • Patent number: 11072653
    Abstract: The present invention is directed to the anti-LAG-3 antibodies, LAG-3 mAb 1, LAG-3 mAb 2, LAG-3 mAb 4, LAG-3 mAb 5, and LAG-3 mAb 6, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to LAG-3-binding molecules that comprise LAG-3 binding fragments of such anti-LAG-3 antibodies, immunocongugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such LAG-3-binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cells. The present invention also pertains to methods of detecting LAG-3, as well as methods of using molecules that bind LAG-3 for stimulating immune responses.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: July 27, 2021
    Assignee: MacroGenics, Inc.
    Inventors: Ross La Motte-Mohs, Kalpana Shah, Douglas H. Smith, Leslie S. Johnson, Paul A. Moore, Ezio Bonvini, Scott Koenig
  • Patent number: 11067634
    Abstract: A method for estimating a state of charge of a battery includes obtaining a discharge voltage and discharge capacity curve of a battery under a preset discharge current, in responding to an order for estimating the state of charge of the battery; matching the discharge voltage and discharge capacity curve with a plurality of standard curves in a database, thereby obtaining an optimal matching curve with respect to the discharge voltage and discharge capacity curve; and calculating the state of charge of the battery according to the optimal matching curve, under a preset discharge stage. The present method can accurately calculate the state of charge of the battery with simple calculation manners.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: July 20, 2021
    Assignee: THE HKUST FOK YING TUNG RESEARCH INSTITUTE
    Inventors: Ka Chung Chan, Lung Fai Moses Ng, Chi Li Wu, Yu Hang Christopher Chao
  • Patent number: 11066465
    Abstract: Provided herein are anti-VEGF-A antibodies and antibody conjugates thereof. Some embodiments of the antibodies can be conjugated to a moiety, such as a HEMA-PC polymer. Some embodiments of the antibody conjugates can retain or enhance antibody activity. The antibody and conjugate thereof can be particularly useful for treating diabetic retinopathy. Further provided are methods for conjugation of a polymer to a protein such as an antibody, such as IgG1.
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: July 20, 2021
    Assignee: KODIAK SCIENCES INC.
    Inventors: Daniel Victor Perlroth, Wah Yuen To, Hong Liang
  • Patent number: 11059885
    Abstract: The present disclosure relates to fusion molecules and chimeric molecules which comprise two components: an Ang-2 antagonist peptide linked to a VEGF-binding moiety. Further disclosed are methods of using said chimeric molecules to treat a patient cancer, proliferative retinopathy, neovascular glaucoma, macular edema, wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), or diabetic retinopathy (DR).
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: July 13, 2021
    Assignee: AskGene Pharma Inc.
    Inventors: Yuefeng Lu, Jian-Feng Lu
  • Patent number: 11059898
    Abstract: Through a combination of in vitro and in vivo approaches, the inventors show that human IgG2 (h2) delivers unique Fc?R-independent agonistic activity to anti-CD40 antibodies and to antibodies specific to other immunostimulatory receptors, including 4-1BB and CD28. Investigation of an anti-human CD40 mAb, LOB7.4, revealed that the unique activity of h2 was dependent upon the precise arrangement of hinge and CH1 disulfide bonds. Chemical ‘shuffling’ or mutagenesis to ‘lock’ LOB7.4 into either a more flexible ‘h2A’ or more compact ‘h2B’ conformation endowed antagonistic and agonistic properties, respectively. Engineering of h2 in this way allows development of reagents with either immunostimulatory or immunosuppressive characteristics, with direct implication for the design of therapeutic mAb agents and fusion proteins.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: July 13, 2021
    Assignee: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Martin J. Glennie, Ann White
  • Patent number: 11058770
    Abstract: A stable protein ionic liquid, comprising an anti-hemoglobin cation/anion pair. The anti-hemoglobin cation/anion pair may be an anionic polymer of poly(ethylene glycol) 4-nonylphenyl 3-sulfopropyl ether. The anti-hemoglobin cation/anion pair may further comprise a cationized anti-hemoglobin antibody, single-chain antibodies from camelids, antibody fragments, polyclonal Anti-horse spleen ferritin antibodies, monoclonal Anti-Flag antibodies, monoclonal Anti-HRP2 to Plasmodium falciparum, polyclonal Anti-neuropeptide Y, polyclonal Anti-human troponin, isotypes of antibodies, or combinations of multiple antibodies.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: July 13, 2021
    Assignee: United States of America as represented by the Secretary of the Air Force
    Inventors: Joseph M Slocik, Rajesh R. Naik, Patrick B Dennis
  • Patent number: 11062804
    Abstract: System and method for validating algorithms used in medical devices is disclosed. As disclosed, the system and method include generating a synthetic waveform, inputting the generated synthetic waveform to the testing device, capturing an output values for the input values generating synthetic waveform from the testing device; and comparing the output values to the input values to determine performance metrics of the testing device to validate the algorithm on the testing device.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: July 13, 2021
    Assignee: VITAL CONNECT, INC.
    Inventors: Nandakumar Selvaraj, Paul Kettle
  • Patent number: 11058776
    Abstract: Disclosed is an IgG Fc fragment useful as a drug carrier. A recombinant vector expressing the IgG Fc fragment, a transformant transformed with the recombinant vector, and a method of preparing an IgG Fc fragment are disclosed. When conjugated to a certain drug, the IgG Fc fragment improves the in vivo duration of action of the drug and minimizes the in vivo activity reduction of the drug.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: July 13, 2021
    Assignee: HANMI SCIENCE CO., LTD.
    Inventors: Sung Youb Jung, Jin Sun Kim, Geun Hee Yang, Se Chang Kwon, Gwan Sun Lee
  • Patent number: 11053302
    Abstract: The present invention relates to single domain antibodies comprising at least one modification relative to the 4D5 antibody scaffold or human germline VH3 domain, the modifications selected from the group consisting of H35D, A78V, S93V, S93G and W103R, with the position numbering being according to the Kabat numbering scheme. Disulfide-free variants further comprise at least one additional modification selected from the group consisting of C22S, A24I, A24L and C92T, and with the proviso that at least one of C22S and C92T is present. Further encompassed are the multi-modular antibody molecules and antibody conjugates comprising single domain antibodies, as well as methods for producing them. The invention in particular provides a library of the single domain antibodies or multi-modular antibody molecules and a method for selecting an antibody that binds an antigen.
    Type: Grant
    Filed: November 4, 2015
    Date of Patent: July 6, 2021
    Assignee: Nanyang Technological University
    Inventors: Tobias Carl Cornvik, Ignacio Jose Asial, Par Lennart Nordlund
  • Patent number: 11046954
    Abstract: This invention is in the area of compositions and methods for regulating chimeric antigen receptor immune effector cell, for example T-cell (CAR-T), therapy to modulate associated adverse inflammatory responses, for example, cytokine release syndrome and tumor lysis syndrome, using targeted protein degradation.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: June 29, 2021
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: James Bradner, Justin Roberts, Behnam Nabet, Georg Winter, Andrew J. Phillips, Timothy Heffernan, Dennis Buckley
  • Patent number: 11047837
    Abstract: Systems, methods and computer program products for cannabis analysis, such as a system that has a cannabis analysis data server and a plurality of mobile cannabis analysis devices that are communicatively coupled to a network. The mobile devices perform physical analyses of a physical sample and communicate resulting data to the cannabis analysis data server with a unique identifier. The mobile cannabis analysis devices may also monitor device and external environmental conditions that affect the performance and communicate these to the cannabis analysis data server. The cannabis analysis data server performs analyses on the received data from the mobile devices. Based on the sample analyses, the cannabis analysis data server generates sample analysis reports and communicates them to a user. The cannabis analysis data server may also generate data to control the operation of the mobile cannabis analysis devices based on the operation and environmental data received from the devices.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: June 29, 2021
    Assignee: Green Ocean Sciences, Inc.
    Inventors: Alexander Fayek Andrawes, David Cree Crawford, Craig Fontenot, Quan Shi
  • Patent number: 11040110
    Abstract: Disclosed is a protein complex, comprising a physiologically active polypeptide, a dimeric protein and a non-peptidyl polymer having three functional ends (3-arm), with the linkage of both the physiologically active polypeptide and the dimeric protein to the 3-arm non-peptidyl polymer via respective covalent bonds. The protein complex guarantees the long acting activity and biostability of a physiologically active polypeptide. Having the ability to maintain the bioactivity of physiologically active polypeptides or peptides highly and to significantly improve the serum half life of the polypeptides or peptides, the protein complex can be applied to the development of sustained release formulations of various physiologically active polypeptide drugs. Also, it utilizes raw materials including the physiologically active polypeptides without significant loss, thereby increasing the production yield. Further, it can be easily purified.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: June 22, 2021
    Assignee: HANMI SCIENCE CO., LTD.
    Inventors: Dae Hae Song, Jae Hee Shin, Mi Ji Lee, Sung Hee Hong, Se Chang Kwon, Gwan Sun Lee
  • Patent number: 11034772
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Grant
    Filed: October 8, 2020
    Date of Patent: June 15, 2021
    Assignee: GENMAB HOLDING B.V.
    Inventors: Simone Oostindie, Frank Beurskens, Esther Breij, Edward Van Den Brink, Andreas Hollenstein, Marije Overdijk, Margaret Lindorfer, Ronald Taylor, Paul Parren, Hilma Van Der Horst, Martine E. D. Chamuleau, Tuna Mutis
  • Patent number: 11035703
    Abstract: A sensor arrangement mode acquisition device capable of acquiring an arrangement mode of sensors while evaluating a detection accuracy of a predetermined action and a limitation on the number of sensors is provided. An E2PROM (13) of a sensor arrangement mode acquisition device (1) stores a database that defines a relationship between k×m correct answer ratios when the number of sensors (2) within a range of n or less is disposed in a test subject in k different arrangement modes, the k arrangement modes, and m predetermined actions. A controller (10) acquires one or more arrangement modes from the database in a case where an upper limit number of sensors, a predetermined action, and attachment areas of the sensors are selected by operating an input device (12) and a result display button (27) is pressed, and displays the acquired arrangement modes on a display (11).
    Type: Grant
    Filed: March 5, 2020
    Date of Patent: June 15, 2021
    Assignee: Honda Motor Co., Ltd.
    Inventor: Taizo Yoshikawa
  • Patent number: 11034775
    Abstract: The present disclosure involves biologically active proteins termed cysteine-optimized multimerizing stradomers. Thus, the present disclosure provides compositions and methods providing anti-autoimmune and anti-inflammatory activities, useful in the treatment of diseases and conditions including autoimmune diseases, inflammatory diseases, or infectious diseases.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: June 15, 2021
    Assignee: GLIKNIK INC.
    Inventors: Henrik Olsen, David S. Block
  • Patent number: 11026995
    Abstract: The present invention relates to the use of a CD24 protein for lowering low-density lipoprotein cholesterol levels, treating and preventing atherosclerosis, and for reducing risk of cardiovascular disease.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: June 8, 2021
    Assignee: ONCOIMMUNE, INC.
    Inventors: Yang Liu, Pan Zheng
  • Patent number: 11027003
    Abstract: The present invention provides a WT1-derived HLA-DRB1*0405-binding antigen peptide, a polynucleotide encoding said peptide, a helper T cell inducer comprising said peptide or polynucleotide, and the like. It is related to a partial peptide consisting of 10-25 contiguous amino acids in the amino acid sequence of human WT1 shown in SEQ ID NO: 1, which binds to HLA-DRB1*0405 and induces helper T cells, a polynucleotide encoding said peptide, or a helper T cell inducer comprising said peptide or polynucleotide.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: June 8, 2021
    Assignee: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
    Inventor: Haruo Sugiyama
  • Patent number: 11029364
    Abstract: In order to determine the charging capacity state and the state of health of an electrical energy store of a battery system (BS1; BS2) with little effort, a measuring device (ME) is proposed, which measuring device injects, into a drive train which is available for first or second loads (VR1; VR2) and has an AC/DC converter (ADC) or a DC/DC controller (DDC) on the DC side of the AC/DC converter (ADC) or of the DC/DC controller (DDC), a sinusoidal voltage harmonic with a varied frequency or a sinusoidal current with a varied frequency as a particular measurement signal which is transmitted to the battery system (BS1; BS2). The current response or voltage response, which has been purged of unwanted influences, is then determined for each measurement signal at the battery system (BS1; BS2), from which response phase shifts are determined in each case, and parameters for a statement relating to the charging capacity state or the state of health of the battery system (BS1; BS2) are in turn determined therefrom.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: June 8, 2021
    Assignee: Rolls-Royce Deutschland Ltd & Co KG
    Inventor: Andreas Meyer
  • Patent number: 11020478
    Abstract: A method for modulating angiogenesis in a cancer or tumor refractory to anti-VEGF, including identifying a cancer cell as being referactory to anti-VEGF, and then contacting the cancer cell refractory to anti-VEGF with an effective amount of an agent that modulates interaction between Gal1 or a Gal1 fragment and the natural binding partner of Gal1 or the Gal1 fragment to thereby modulate angiogenesis.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: June 1, 2021
    Assignees: Inis Biotech LLC, Consejo Nacional de Investigaciones Científicas y Técnicas, Funadción Sales
    Inventors: Gabriel Adrian Rabinovich, Diego Omar Croci Russo, Juan Pablo Cerliani, Mariana Salatino, Pablo Francisco Hockl, Juan Manuel Pérez Sáez